Introduction
============

Current guidelines regarding use of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) are based on data derived from randomized clinical trials, which were mostly conducted in younger patients,[@b1-cia-10-1547]--[@b3-cia-10-1547] although a substantial number of patients with ACS are aged ≥80 years. The available data in patients with ACS aged ≥80 years are of short term and are mainly registry derived.[@b4-cia-10-1547]--[@b6-cia-10-1547] Mid- and long-term data regarding PCI in octogenarians are not only very limited but also inconsistent.[@b7-cia-10-1547]--[@b10-cia-10-1547] For instance, incidence rates of major adverse cardiac events, defined as the combined events of death, revascularization, and myocardial infarction (MI), among elderly patients have been found to be higher than younger patients in some studies but similar to younger patients in other studies.[@b7-cia-10-1547]--[@b10-cia-10-1547] Moreover, available observational studies have demonstrated that older age is associated with both higher in-hospital mortality and frequent complications such as renal failure and bleeding after PCI.[@b11-cia-10-1547],[@b12-cia-10-1547]

Because of the paucity and inconsistency of data on the use of PCI in octogenarians in daily clinical practice, it is difficult for physicians to make well-grounded decisions on the use of PCI in these patients. Elderly patients have been found to be less likely than younger ones to undergo PCI, despite that it is contrary to prevailing ethical principles when PCI is withheld from elderly patients solely because of their older age. Nevertheless, there are existing data suggesting that older age is associated with negative outcomes.[@b13-cia-10-1547]--[@b15-cia-10-1547] Moreover, the elderly constitute a heterogeneous group. The term "elderly" is a broad term comprising the "young" old (65--74 years), the "older" old (75--84 years), and the "oldest" old (≥85 years),[@b16-cia-10-1547] with considerable individual variation in comorbidities and physical capabilities. Undoubtedly, it is essential to address whether PCI can improve survival in an octogenarian group with ACS irrespective of their age and comorbidities. So far, there were two trials studying an aggressive approach in comparison with a conservative strategy. In a randomized study of 313 patients ≥75 years of age with non-ST-segment elevation ACS, an early aggressive approach (coronary angiography, and when indicated, revascularization within 72 hours) resulted in a significant reduction in the primary endpoint (the composite of death, MI, disabling stroke, and repeated hospital stay for cardiovascular causes or severe bleeding within 1 year) in patients with elevated troponin on admission but not in those with normal troponin. Because of this significant interaction of the treatment effect according to troponin status at baseline, the benefit of an early aggressive approach among elderly patients with non-ST-segment elevation ACS was not conclusive.[@b17-cia-10-1547] Recently, in a multicenter study conducted at the American College of Cardiology (ACC) on March 16, 2015, Tegn et al (unpublished data, 2015) reported that 457 stable ACS patients \>80 years old were randomized to an invasive (n=229) or conservative strategy (n=228). In this study, those who underwent an invasive strategy had a decrease in the primary composite endpoint (MI, need for urgent revascularization, stroke, and death) at a median follow-up of 18 months as compared with a conservative approach (not published yet). However, no prospective, randomized, controlled clinical trials are available to compare head to head between PCI-treated and non-PCI-treated patients with ACS aged ≥80 years. Therefore, decision-making about performing PCI in this age group remains highly empirical. The aim of the present study was to assess the association between PCI and long-term mortality in octogenarians with ACS.

Materials and methods
=====================

Study cohort
------------

Three hundred and fifty-three patients aged ≥80 years who were hospitalized due to ACS, during 2006--2007 at two university hospitals (Sahlgrenska and Östra) affiliated with the University of Gothenburg, were included consecutively, and studied from January 2 to May 30, 2012. Among them, 182 were treated with PCI, whereas 171 were not. Patients came directly from ambulance or were referred from cardiology and medical departments at both hospitals. Treatment with PCI or no treatment was based on a pure clinical decision made by responsible cardiologist. All PCIs were performed at a joint PCI center for both hospitals. The time period 2006--2007 was chosen to allow for a follow-up period of at least 5 years. Patients were identified from the hospital registry. In cases that two or more PCI procedures were performed in the same patient, only the first PCI the individual patient underwent at an age ≥80 years was studied. Two exclusion criteria for the study were applied. Firstly, patients belonging to other hospitals but undergoing PCI at our center were excluded due to the lack of medical records. Secondly, since the objective of the study was to evaluate the prognosis after PCI in ACS, elective PCI procedures with the indication of stable angina pectoris were excluded. This is based on the fact that the current PCI indication in case of stable angina is to relieve symptoms rather than for prognostic benefit. The study protocol was approved by the Ethical Committee at the University of Gothenburg.

Statistics
----------

The results are presented as percentages and the mean ± standard deviation. In the case of continuous variables that visual inspection of their histograms, normal *Q*--*Q* plots and box plots showed that the variables were approximately normally distributed. Statistical analysis was performed using Student's unpaired *t*-test. Mann--Whitney test was used for non-normally distributed continuous variables. For discrete variables, the chi-square test was used. A *P*-value \<0.05 was regarded as statistically significant. The hazard ratios (HRs) from Cox survival analysis with confidence intervals (CIs) and *P*-values were presented. Propensity score (PS)-matching analysis with 1:1 nearest neighbor matching was employed. Variables used in developing the PS are presented in [Table 1](#t1-cia-10-1547){ref-type="table"}. These variables were chosen based on clinical relevance. As shown in [Figure 1](#f1-cia-10-1547){ref-type="fig"}, the covariate balance was improved in the matched sample, that the region of common support spanned almost the entire distribution of the PS, and that it was only in the extreme tail regions that no appropriate matching could be found. After PS matching, 142 patients remained including 71 in the PCI-treated and 71 in non-PCI-treated groups.

Both the overall cohort and the PS-matched cohort were further analyzed by Cox proportional-hazard regression models. Variables with clinical relevance and significant results from univariable Cox models were included in multivariable models ([Table 2](#t2-cia-10-1547){ref-type="table"}). Cox models were assessed for proportional-hazard assumption for covariates, graphically with Cox-adjusted log minus log curves and statically using Schoenfeld global test. Survival rates are presented both as adjusted Cox regression survival curves and as Kaplan--Meier curves with log rank test for comparisons.

Clinical outcome data
---------------------

All clinical variables are based on medical records. The primary endpoint was all-cause mortality based on data from the death registry of the National Board of Health and Welfare in Sweden, which were available for all studied patients during the time period from January 2 to May 30, 2012.

Results
=======

Clinical characteristics of the PCI-treated and non-PCI-treated group
---------------------------------------------------------------------

As shown in [Table 1](#t1-cia-10-1547){ref-type="table"}, in the overall cohort, the PCI-treated group was younger and more frequently male, and had less stroke and dependency in activities of daily living, higher left ventricular ejection fraction, and more often treatment with clopidogrel and statins compared with those in the non-PCI-treated group. But no significant differences in occurrence of diabetes mellitus, chronic obstructive pulmonary disease, hypertension, and uncured malignancies were found between the two groups.

Indications for PCI were ST-segment elevation MI (STEMI; 52%), non-ST-segment elevation MI (NSTEMI; 36%), and unstable angina (11%). In non-PCI group, 14%, 81%, and 5% of patients had STEMI, NSTEMI, and unstable angina, respectively. Among PCI-treated patients, only two received drug-eluting stent, 51% had three-vessel coronary artery disease, and only 21% had one-vessel coronary artery disease. Moreover, 57% received stent in left circumflex coronary artery or in left anterior descending coronary artery and only 4% in left main coronary artery. After PS matching, 142 patients remained including 71 in the PCI-treated and 71 in non-PCI-treated groups. As shown in [Figure 1](#f1-cia-10-1547){ref-type="fig"}, the covariate balance was improved in the matched sample, that the region of common support spanned almost the entire distribution of the PS, and that it was only in the extreme tail regions that no appropriate matching could be found.

All-cause 5-year mortality between the PCI-treated and non-PCI-treated groups
-----------------------------------------------------------------------------

In the overall cohort (n=353), all-cause mortality was 46.2% (84 events) and 89.5% (153 events) in those treated with PCI and those not treated with PCI, respectively. After PS matching (n=142), all-cause mortality was 54.9% (39 events) and 83.1% (59 events) in the PCI and non-PCI subgroups, respectively. Kaplan--Meier survival curves and log rank test (*P*=0.001) showed significantly improved survival in patients treated with PCI compared with patients not treated with PCI. The 5-year mean survival time after PCI was 48 months (95% CI 41--54), whereas 5-year mean survival time without PCI was 35 months (95% CI 29--42) ([Figure 2](#f2-cia-10-1547){ref-type="fig"}).

Associations between PCI and long-term mortality
------------------------------------------------

A Cox proportional-hazard regression analysis was performed to assess association between PCI and long-term mortality, both in overall cohort and in propensity-matched cohort. In overall cohort (n=353), Cox regression analysis showed that treatment with PCI was associated with reduced 5-year all-cause mortality (HR 0.4 with 95% CI 0.3--0.6, *P*\<0.001) after adjustment for ten baseline variables ([Table 2](#t2-cia-10-1547){ref-type="table"} and [Figure 3](#f3-cia-10-1547){ref-type="fig"}). Moreover, in propensity-matched group, PCI was still associated with reduced 5-year all-cause mortality (HR 0.5 with 95% CI 0.2--0.9, *P*=0.020) after adjustment for PS and confounders including age, male sex, cognitive deterioration, uncured malignancies, left ventricular ejection fraction ≤45%, estimated glomerular filtration rate ≤35 mL/min, STEMI, mitral regurgitation, and medication at discharge with clopidogrel and statins ([Table 2](#t2-cia-10-1547){ref-type="table"} and [Figure 4](#f4-cia-10-1547){ref-type="fig"}).

Discussion
==========

Our study demonstrated that in an octogenarian patient cohort presenting with ACS from daily clinical practice, there was an association between PCI and reduced all-cause death over 5 years of follow-up.

In overall cohort, there was a significant association between reduction in 5-year all-cause mortality and PCI. But due to differences in baseline characteristics between the two groups, a PS-based matching was performed. It is interesting to note that there was a similar association between all-cause mortality and PCI even in the PS-matched cohort. Consequently, PCI had a strong association with improved survival in our octogenarian cohort despite PS matching and adjustment with Cox proportional-hazard regression. Therefore, our study implies that among patients aged ≥80 years, there is a potential prognostic benefit of PCI in patients presenting with ACS. In view of the fact that there are no prospective, randomized, controlled clinical trials available to compare head to head between PCI-treated and non-PCI-treated patients with ACS aged ≥80 years, our results are hypothesis-generating and suggest that efficacy of PCI warrants further study in octogenarian ACS patients.

Our results are in line with recently published trials. Savonitto et al demonstrated that an early aggressive approach (coronary angiography, and when indicated, revascularization within 72 hours) resulted in a significant reduction in the primary endpoint (the composite of death, MI, disabling stroke, and repeated hospital stay for cardiovascular causes or severe bleeding within 1 year) in elderly patients with non-ST-segment elevation ACS. However, in this study, this positive outcome only occurs in those with elevated troponin on admission.[@b17-cia-10-1547] In another multicenter study by Tegn et al elderly ACS patients who underwent an invasive strategy had a decrease in the primary composite endpoint (MI, need for urgent revascularization, stroke, and death) as compared with a conservative approach (not published yet). However, it is noteworthy to mention that there are several differences between above randomized studies and our retrospective study. For the first, in above-mentioned two randomized studies, it is an early invasive approach that was studied, that is, PCI only when indicated, in comparison with conservative strategy. This implies that not all patients in the group assigned to invasive approach have undergone PCI. However, our study aimed to compare between PCI and non-PCI treatment. For the second, patient population included in above-mentioned randomized studies were either NSTEMI or stable ACS patients. Presumably, patients with unstable ACS or STEMI with strong clinical indication for acute PCI were excluded for randomization because of ethical reasons. However, in our study, because of nature of retrospective study, there were no pre-specified criteria for PCI rather than on the basis of clinical decision of responsible physician. Therefore, all patients with ACS including STEMI and cardiogenic shock were included.

Study limitations/strengths
---------------------------

In this study, secondary medical record data were used. Despite our efforts in catching up as much information as possible, there were still some data missing. Despite PS adjustment, we cannot rule out residual confounding from unmeasured variables. Therefore, our results need to be confirmed in a randomized controlled study in the future. Nevertheless, our data are encouraging and serve as the basis for generating hypothesis in future randomized trials. The strength of our study is that all patients were included from our daily clinical practice; therefore, the generalizability should be regarded as higher than those of randomized, controlled, clinical trials.

Conclusion
==========

In an octogenarian patient cohort with ACS in daily clinical practice, PCI was associated with reduced all-cause death over 5 years of follow-up.
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###### 

Characteristics of the overall and matched cohorts; comparison between the groups treated with or not treated with PCI

                                   Missing (%)   Before propensity matching   After propensity matching                                   
  -------------------------------- ------------- ---------------------------- --------------------------- --------- ---------- ---------- -------
  Median age (years) (range)       0             86 (19)                      83 (13)                     \<0.001   84 (13)    84 (13)    0.885
  Male sex, n (%)                  0             67 (39)                      112 (61)                    \<0.001   35 (49)    36 (50)    0.876
  Mean BMI (kg/m^2^) (SD)          20            24 (4)                       25 (3)                      0.059     24 (4)     24 (4)     0.607
  Dependency in ADL, n (%)         6             35 (13)                      11 (6)                      \<0.001   7 (9)      6 (8)      0.851
  Medical history, n (%)                                                                                                                  
   Diabetes mellitus               0             34 (20)                      38 (20)                     0.849     16 (23)    16 (22)    0.930
   Hypertension                    0             117 (68)                     119 (65)                    0.521     51 (71)    47 (66)    0.468
   Hypercholesterolemia            0.5           10 (5)                       33 (18)                     \<0.001   8 (11)     8 (11)     1.000
   Prior PCI                       0.5           17 (8)                       12 (6)                      0.696     4 (5)      6 (9)      0.463
   Heart failure                   6             55 (32)                      39 (21)                     0.030     20 (28)    13 (18)    0.205
   Stroke                          0             43 (25)                      21 (11)                     \<0.001   11 (15)    10 (14)    0.813
  Clinical findings                                                                                                                       
   Heart rate (bpm) (SD)           5             86 (21)                      79 (24)                     0.086     85 (21)    80 (15)    0.167
   Atrial fibrillation, n (%)      7             42 (24)                      37 (20)                     0.342     17 (24)    22 (31)    0.324
   SBP (mmHg), mean (SD)           6             143 (27)                     150 (27)                    0.528     145 (23)   147 (27)   0.659
   DBP (mmHg), mean (SD)           6             82 (15)                      85 (16)                     0.118     83 (14)    84 (17)    0.711
  Laboratory findings, mean (SD)                                                                                                          
   Hemoglobin (g/L)                10            126 (18)                     133 (16)                    \<0.001   127 (16)   130 (17)   0.318
   eGFR (mL/min)                   8             41 (20)                      53 (17)                     \<0.001   47 (21)    49 (17)    0.647
  Medications at discharge (%)                                                                                                            
   Aspirin                         12            119 (83)                     146 (88)                    0.142     56 (85)    59 (88)    0.588
   Beta-blockers                   12            124 (87)                     152 (92)                    0.121     60 (92)    63 (94)    0.692
   ACEIs                           3             51 (35)                      89 (54)                     0.001     30 (45)    40 (60)    0.081
   ARBs                            3             9 (6)                        19 (14)                     0.111     4 (6)      8 (12)     0.226

**Notes:**

Comparison of differences between the groups using *t*-test for normally distributed continuous variables, Mann--Whitney test for non-normally distributed continuous variables, and chi-square test for categorical variables.

**Abbreviations:** PCI, percutaneous coronary intervention; BMI, body mass index; SD, standard deviation; ADL, activities of daily living; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.

###### 

Univariable[+](#tfn3-cia-10-1547){ref-type="table-fn"} and multivariable Cox regression analyses for relationship between PCI and long-term all-cause mortality

                                                                                     Univariable      Multivariable                    
  ---------------------------------------------------------------------------------- ---------------- --------------- ---------------- ---------
  In overall cohort                                                                                                                    
   Unadjusted                                                                        0.3 (0.2--0.4)   \<0.001         --               --
   Adjusted for the confounders[\*](#tfn4-cia-10-1547){ref-type="table-fn"}          --               --              0.4 (0.2--0.5)   \<0.001
  In matched cohort                                                                                                                    
   Unadjusted                                                                        0.5 (0.3--0.7)   0.002           --               --
   Adjusted for PS                                                                   --               --              0.6 (0.2--1.9)   0.003
   Adjusted for PS and the confounders[\*](#tfn4-cia-10-1547){ref-type="table-fn"}   --               --              0.5 (0.2--0.9)   0.020

**Notes:**

Baseline variables including in univariable models: age, male sex, cognitive deterioration, diabetes mellitus, hypertension, uncured malignancies, left ventricular ejection fraction ≤45%, estimated glomerular filtration rate ≤35 mL/min, ST-segment elevation myocardial infarction, atrial fibrillation, mitral regurgitation, chronic obstructive pulmonary disease, and medications at discharge with clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins.

Confounders including in multivariable models: age, male sex, cognitive deterioration, left ventricular ejection fraction ≤45%, uncured malignancies, estimated glomerular filtration rate ≤35 mL/min, ST-segment elevation myocardial infarction, mitral regurgitation, and medications at discharge with clopidogrel and statins.

**Abbreviations:** PCI, percutaneous coronary intervention; HR, hazard ratio; CI, confidence interval; PS, propensity score.
